A researcher at University of Pennsylvania has come up with an alternative payment model that could encourage pharmaceutical companies to invest in expensive gene therapies, often consisting of a single treatment. They suggest annuity payments over a defined period of time and contingent on evidence that the treatment remains effective. The approach would replace the current practice of single, usually large, at-point-of-service payments. "Unlike most rare disease ...Thursday 11 September 2014
Penn Researcher Comes Up With Alternate Payment Model to Encourage Pharma Investment in Expensive Gene Therapies
A researcher at University of Pennsylvania has come up with an alternative payment model that could encourage pharmaceutical companies to invest in expensive gene therapies, often consisting of a single treatment. They suggest annuity payments over a defined period of time and contingent on evidence that the treatment remains effective. The approach would replace the current practice of single, usually large, at-point-of-service payments. "Unlike most rare disease ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment